News and Announcements
Series 1 of the Warburton Global Fund returned -2.0% in first month of 2019
- Published February 06, 2019 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Series 1 units of the Warburton Global Fund returned -2.0% in January 2019. The value of $1 invested since inception is $1.48.
Markets that had been sold down in 2018, bounced sharply in January. Equities rallied strongly in all jurisdictions, yet not enough in most major markets to recoup the losses in December.
Commodity prices surged across the board. Industrial metal prices bounced hard while precious metal and uranium prices continued their bull market rallies.
After falling 40% in Q4 2018, oil bounced 18%. The AUD had a really strong month versus the USD. Bonds gained in value, albeit more moderately than most other asset classes. The 2-year to 10-year section of the US yield curve continued to flatten.
About Warburton Investment Management
Warburton Investment Management manages client capital via the Warburton Global Fund, a global macro hedge fund that deals in international investments. The fund invests in public equity, fixed income, currency and commodity markets worldwide.
Founded in 2015, Warburton Investment Management is one of the best performing firms in the hedge fund industry, with a mandate to target annualised returns of over 30%.
Company Updates
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Backed By Leading Investment Groups and Family Offices
